Ching-Min Li

The two probiotic strains used were Lactobacillus salivarius AP-32 (BCRC 910437, CCTCC M2011127), originally isolated from the gastrointestinal tract of healthy individuals, and Bifidobacterium animalis subsp. lactis CP-9 (BCRC 911195, CCTCC M2014588), sourced from the breast milk of healthy mothers. Each probiotic capsule, containing 5 × 10⁹ CFU, was provided by Glac Biotech Co., Ltd. (Tainan, Taiwan) and was visually indistinguishable from the placebo capsules, which contained only maltodextrin.

Both probiotic treatments were found to be well tolerated and safe for usage over this period, with no differences in digestive tolerance, occurrence of adverse events, or crying/fussing time when compared to the placebo group. The Taiwanese researchers emphasised: “Our study findings indicate that the oral administration of both AP-32 and CP-9 strains has a positive impact on the maintenance of a healthy gut flora in infants. “Long-term use of L. salivarius AP-32 or B.

Font Type: Arial Georgia Verdana Line Spacing:    Column Width:    Open AccessArticle by 1,†, 2,†, 1, Neonatal Probiotic Use and Safety Research Group 3,‡, 1, 4,5 and 1,* 1 Department of Research and Design, Glac Biotech Co., Ltd., Tainan 744, Taiwan 2 Department of Pediatrics, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung 833, Taiwan 3 Chang Gung Memorial Hospital, Taoyuan 333, Taiwan 4 Aging and Disease Prevention Research Center, Fooyin...